Oragenics

Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate in Two Investment Conferences During March

Oragenics to Participate in Two Investment Conferences During March

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

TAMPA, Fla.--(BUSINESS WIRE)--SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice

SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice

Oragenics (OGEN) stock is soaring higher on Thursday from new coronavirus vaccine news after just receiving a boost last week. The post OGEN Stock Alert: Why Oragenics Shares Are Flying Again Thursday appeared first on InvestorPlace.

OGEN Stock Alert: Why Oragenics Shares Are Flying Again Thursday

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Issues Letter to Stockholders

Oragenics Issues Letter to Stockholders

Oragenics (OGEN) is seeing shares of OGEN stock take off on Thursday on a news update for its vaccine to treat the novel coronavirus. The post OGEN Stock Alert: 14 Things to Know About Oragenics as Shares Rocket Thursday appeared first on InvestorPlace.

OGEN Stock Alert: 14 Things to Know About Oragenics as Shares Rocket Thursday

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT

Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ANNOUNCES CLOSING OF $6.5 MILLION REGISTERED DIRECT OFFERING

Oragenics Announces Closing of $6.5 Million Registered Direct Offering

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING

Oragenics Prices $5.25 Million Common Stock Offering

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Proposed Underwritten Public Offering

CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public Offering

Oragenics is planning to launch clinical trials of its coronavirus vaccine in early 2021. OGEN stock is soaring on the news.

OGEN Stock: Why Oragenics Is Soaring 25%

TAMPA, Fla.--(BUSINESS WIRE)--FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Inc.

Oragenics Inc. to Present at the H.C.

Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

TAMPA, Fla.--(BUSINESS WIRE)--Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

News for Oragenics Stock (OGEN)